机构：[1]Capital Med Univ, Dept Pharm, Xuanwu Hosp, 45 Changchun St, Beijing, Peoples R China首都医科大学宣武医院[2]Natl Clin Res Ctr Geriatr Disorders, Beijing, Peoples R China
In this article, we have carefully read the author's comments on our published article regarding the post-marketing safety concerns of lecanemab based on the Food and Drug Administration Adverse Event Reporting System (FAERS) database. Pharmacovigilance studies based on the disproportionality analysis through the case/non-case design are common, and the details of this method deserve attention. We acknowledged the author's perspectives on the term "signal of disproportionate reporting (SDR)", and make some explanations on the SDR results for pancreatic carcinoma and the deduplication methods.
第一作者机构：[1]Capital Med Univ, Dept Pharm, Xuanwu Hosp, 45 Changchun St, Beijing, Peoples R China[2]Natl Clin Res Ctr Geriatr Disorders, Beijing, Peoples R China
共同第一作者：
通讯作者：
通讯机构：[1]Capital Med Univ, Dept Pharm, Xuanwu Hosp, 45 Changchun St, Beijing, Peoples R China[2]Natl Clin Res Ctr Geriatr Disorders, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Xing Xiaoxuan,Wang Ke,Dong Xianzhe.Reply: [Post-marketing safety concerns with Lecanemab: a disproportionality analysis using the FDA adverse event reporting system[J].ALZHEIMERS RESEARCH & THERAPY.2025,17(1):doi:10.1186/s13195-025-01728-4.
APA：
Xing, Xiaoxuan,Wang, Ke&Dong, Xianzhe.(2025).Reply: [Post-marketing safety concerns with Lecanemab: a disproportionality analysis using the FDA adverse event reporting system.ALZHEIMERS RESEARCH & THERAPY,17,(1)
MLA：
Xing, Xiaoxuan,et al."Reply: [Post-marketing safety concerns with Lecanemab: a disproportionality analysis using the FDA adverse event reporting system".ALZHEIMERS RESEARCH & THERAPY 17..1(2025)
医学